NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $49,545,943.00 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

NeuroPace Trading Up 0.1 %

NeuroPace stock traded up $0.02 during trading on Thursday, reaching $13.47. 55,386 shares of the company were exchanged, compared to its average volume of 220,546. The stock’s 50 day simple moving average is $12.37 and its two-hundred day simple moving average is $9.34. The company has a market capitalization of $402.08 million, a P/E ratio of -13.41 and a beta of 2.05. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace, Inc. has a 52-week low of $5.45 and a 52-week high of $17.47.

Institutional Investors Weigh In On NeuroPace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KCK LTD. purchased a new position in shares of NeuroPace during the 4th quarter worth $58,981,000. Jane Street Group LLC acquired a new position in NeuroPace in the fourth quarter valued at about $1,120,000. Jacobs Levy Equity Management Inc. purchased a new position in NeuroPace during the fourth quarter worth about $639,000. JPMorgan Chase & Co. increased its position in shares of NeuroPace by 440.4% during the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after acquiring an additional 52,829 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of NeuroPace in the 4th quarter valued at approximately $369,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on NPCE shares. UBS Group began coverage on shares of NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price on the stock. Wells Fargo & Company lifted their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. upped their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.